Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders

Paused · Phase 3

Conditions studied: Cocaine Use Disorder

In brief

Changes in the communication of glutamate from one brain structure to another are important in the development of therapy for cocaine use disorders. Our preliminary investigations suggest that drugs that affect glutamate exchange may be effective at promoting and maintaining individuals' abstinence from cocaine. The purpose of this randomized, double-blind, controlled trial is to test various glutamate modulators in conjunction with motivational enhancement therapy (MET) and mindfulness based relapse prevention (MBRP) for cocaine use disorders.

Key facts

Study ID

NCT03344419

Run by

New York State Psychiatric Institute

People needed

150

Starts

2017-10-01

Expected to finish

2024-12-31

Last updated by the study team

2024-07-16

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Meets DSM-V criteria for cocaine use disorders, with at least 1 day of use per week for three weeks over the past month
• Physically healthy
• No adverse reactions to study medications
• 18-70 years of age
• Capacity to consent and comply with study procedures
• Seeking Treatment

You may not qualify if…

• Meets DSM IV criteria for current major depression, bipolar disorder, schizophrenia, any psychotic illness, including substance-induced psychosis, and current substance-induced mood disorder with HAMD score > 12.
• Physiological dependence on another substance, such as alcohol, opioids, or benzodiazepines, excluding caffeine and nicotine, requiring imminent medical management
• Delirium, dementia, amnesia, cognitive disorders, or dissociative disorders
• Current suicide risk or a history of suicide attempt within the 2 years
• Pregnant, interested in becoming pregnant, or lactating
• On psychotropic or other medication whose effect could be disrupted by participation in the study, such as benzodiazepines, opioids, or barbiturates
• Recent history of significant violence
• Heart disease as indicated by history, abnormal ECG, previous cardiac surgery.
• Unstable physical disorders which might make participation hazardous such as hypertension (>160/90), anemia, active hepatitis or other liver disease (transaminase levels < 2-3 X the upper limit of normal will be considered acceptable), or untreated diabetes. Participants reporting HIV+ status will be asked to provide information about their current treatment, including all medications. Participants who are on the antiretroviral ritonavir (Norvir) will be excluded due to the possibility that study medications in combination with this medication may increase the risk of drug-induced hepatitis
• Previous history of a substance use disorder with the study medications or benzodiazepine abuse and/or a history of adverse reaction/ experience with prior exposure to study medications or benzodiazepines

Where it is running

• NYSPI — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.